Skip to content
43

ibu lysin

Skip it

Brand-locked demand (top 5 brands take 98% of clicks) — this niche doesn't clear our bar today.

Market size 43Growth 20Conversion 100Competition 12Returns 100Price range 65Avg price 69Brand share 6Review moat 54Quality gap 14

Conversion

Incredible20.7%

search→purchase rate — share of searches ending in a sale

Returns

Incredible0.0%

return rate — above 6% kills the launch gate

Avg price

Good€14.27

avg listing price — sweet spot $15–$100

Price range

Good€6.48–€31.04

cheapest to priciest tracked listing — scored on the share inside $15–$100

Review moat

Good1,353.7

avg incumbent reviews — the moat a new listing must climb

Market size

Okay€227K

€227K/yr · 77K searches

Growth

Bad-10.8%

90-day search growth — must beat 0% to launch

Quality gap

Bad4.8★

avg incumbent rating — lower means beatable quality

Competition

Bad86%

top-5 click share — a locked-up shelf

Brand share

Bad98%

top-5 brand share — brand-locked demand

Competition

The top 5 products capture 86% of clicks — a locked-up shelf that new listings rarely crack.

Brands

6 falling

Sellers

26

Top-5 brand share

98%

Open market

0%

  • ratiopharm61%
  • Hexal16%
  • STADA15%
  • vitenda3%
  • 1A PHARMA3%
  • ADGC2%
  • Open — no brand owns it (0%)

Product shelf

Each bubble is one product — market share against review moat; bubble size tracks estimated sales, color grades how beatable the incumbent looks.

0%10%€23K20%€45K30%€68K40%€91K1101001K10K Reviews — right = deep review moat Market share (90d) ≈ est. sales
Beatable (≤4.3★) Contested Strong incumbent (>4.7★)

All 10 tracked products in this niche — three views at once, no toggling.

Demand & seasonality

Weekly Amazon search volume, last 104 weeks — -10.8% search growth over the last 90 days.
2K1KSpike '25Prime Day '25SepDecMarJunAugNovMarMay

No pronounced peak months · busiest ÷ quietest = 1.2×